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Available online 1 February 2009The study examined whether verbal intelligence is associated with persisting to take
medication for up to two years. The design is a prospective follow-up of compliance with
taking medication in high-risk individuals participating in a randomised, placebo-controlled
trial set in Central Scotland. Participants were 1993 people aged between 50 and 77 years with
an ankle brachial index ≤0.95. The medication was 100 mg aspirin or placebo daily.
The principal outcome measure was continuing with taking medication or stopping it due to
having ‘changed one's mind’. Higher verbal intelligence was associated with a greater
likelihood of continuing to take medication up to two years after randomisation. For a standard
deviation increase in Mill Hill Vocabulary Scale score, risk of stopping medication in the ﬁrst
two years of the study was 0.75 (95% CI 0.64 to 0.87, pb0.001). Comparing the highest and
lowest quartiles of IQ, the lowest IQ group's relative rate of stopping medication was 2.51 (95%
CI 1.52 to 4.22). The effect was not attenuated after adjustment for sex, smoking, or level of
deprivation. Verbal intelligence is associated with continuing, medium-to-long term
engagement with health self-care, even in the face of uncertainty about whether active
treatment is being received, whether the treatment is known to be effective in general, and
whether it will be helpful to the individual taking it. Such persisting with potentially helpful
health behaviours in the face of uncertainty might partly explain why people with higher
intelligence live longer and suffer less morbidity from chronic diseases.
© 2009 Elsevier Inc. Open access under CC BY license.Keywords:
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Cognitive epidemiology1. Introduction
Higher intelligence (IQ), measured in childhood or early
adulthood, is associated with living longer (Batty, Deary, &
Gottfredson, 2007). The emerging ﬁeld of cognitive epide-
miology aims to establish the limits of this association,
uncover its mechanisms, and explore its implications (Deary
& Batty, 2007). One of the favoured explanations is thatSchool of Philosophy,
urgh 7 George Square,
Y license.intelligence inﬂuences chronic disease onset and ultimately
survival via its association with health behaviours (Gottfred-
son, 2004). This view conceptualises health self-care as a
complex set of tasks that require knowledge, decision-
making, planning, and engagement. It is hypothesised that
people with higher intelligence will manage health self-care
more effectively. Supporting evidence from self-reports
shows that people with higher childhood intelligence tend
to exercise more and have diets that accord better with health
information, are less likely to smoke or to be obese or
overweight, and have fewer hangovers from drinking alcohol
(Batty, Deary, Schoon, & Gale, 2007a,b; Batty, Deary, &
Macintyre, 2006, 2007).
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gence tend to behave more healthily, perhaps being better
able to take a long view about the implications of their
behaviour. They are largely derived from community-based
samples, most of which were too young to be at high risk of
age-related chronic disease. In the present study we shall
inquire whether intelligence inﬂuences self-care and disease
management in individuals with a chronic pathology who are
at moderately increased risk of dying at a younger age. The
setting is a community-based, double-blind, randomised
clinical trial of subjects screened for generalised athero-
sclerosis using the ankle brachial index (ABI) (Price et al.,
2008). Individuals with an increased risk of cardiovascular
events and all-cause mortality—as indicated by a ratio of
systolic blood pressure in the ankle to that in the arm (ABI)
below a pre-determined cut-off (Ankle Brachial Index
Collaboration, 2008)—were randomised to daily low-dose
aspirin or placebo. The present study investigates whether
higher intelligence, measured shortly after randomisation
into the trial, predicted longer-term compliance with study
medication for up to two years in individuals who knew
themselves to be at relatively high risk of cardiovascular
disease.
There is already some information on the factors that
affect older people's compliance with medication, especially
in randomised controlled trials. Some of this research has
concentrated on how compliance varies as a result of the
design of trials and the different interventions used to
enhance compliance (Russell, Conn, & Jantarakupt, 2006).
However, there is variation in compliance even within single
trials, where all participants are exposed to the same regimen
of treatment and encouragements to comply. This motivated
the research for person-level predictors of compliance. A large
quantitative review of compliance with medical recommen-
dations found that older age, female gender, higher income
(but not general socio-economic status), and education were
associated with better compliance (DiMatteo, 2004). The
review lacked information on intelligence. It cannot be
assumed that intelligence—including verbal intelligence,
which will be tested here—is acting as a proxy for education.
Although they are strongly correlated, verbal intelligence is
highly heritable, and large-scale longitudinal data show that
verbal intelligence at age 11 strongly predicts educational
outcomes at age 16 (Deary, Spinath, & Bates, 2006; Deary,
Strand, Smith, & Fernandes, 2007).
It has been suggested that both verbal intelligence and
education are partly-independent contributors to better
health literacy (Paasche-Orlow & Wolf, 2007). Health literacy
is, in turn, posited to be a mediator of the inﬂuence of
intelligence and education on good compliance (Paasche-
Orlow & Wolf, 2007). However, ﬁndings concerning health
literacy and compliance are not univocal, and it is possible
that some so-called health literacy measures are likely to be
acting as little more than verbal ability measures. In a study of
very brief (3-day) compliance with anti-retroviral therapy,
HIV-infected patients with low health literacy were more
likely to show adherence (Paasche-Orlow et al., 2006). The
measure of health literacy was the REALM, which tests people
on their ability to pronounce 66 medically-related words. Of
course, this measure is likely to be related highly to general
vocabulary, which will be tested in the present study as theindependent variable. In a separate study, both education and
health literacy were signiﬁcant, independent predictors of
very brief adherence to combination antiretroviral therapies
in HIV patients (Kalichman, Ramachandran, & Catz, 1999). In
this case, the health literacy measure was the Test of Health
Literacy in Adults, which involves understanding written
passages and numerical information concerning health care
situations. These studies provide examples of two important
omissions in our knowledge concerning the adherence aspect
of personal health management. First, intelligence is arguably
a missing, more fundamental variable, which is prior to, and a
strong determinant of, education and health literacy. There-
fore, associations between intelligence and adherence to
medications should be examined. Second, the adherence in
the above studies is assessed over very short time spans: good
health management involves longer-term adherence to
behaviours that are beneﬁcial to health. This is especially
true among older people where common chronic illnesses,
such as cardiovascular disease, account for a substantial
proportion of the morbidity and mortality burden.
The present study will examine the association between
measured intelligence and a particular aspect of compliance
with health care within a randomised clinical trial. The
participants' intelligence was assessed on average about three
months into the trial. By the time participants had reached
the stage where they took the mental test (the Mill Hill
Vocabulary Scale), they had already made a number of
health-related decisions in the afﬁrmative. First, they
responded positively to the initial contact by the study
team. Second, they attended a non-GP, non-hospital-based
medical research clinic to be assessed. Third, they agreed to
be, and were, randomised to aspirin or placebo treatment.
Fourth, they had persisted with medication for about three
months. Fifth, they agreed to take the Mill Hill Vocabulary
Scale. Therefore, in terms of a model of health-based decision
making, they had already proceeded a long way. Much of
health behaviour and behaviour change research would focus
on the factors that made people make some of these choices—
and intelligence might be associated with any or all of them—
but health self-care with respect to chronic disease involves a
long-standing commitment to experts' recommendations
regarding optimal health behaviours (Gottfredson, 2004). In
the men and women we shall study here, we focus on their
persistence with treatment over the next 21 months of the
study—after a number of ‘good’ initial decisions—that was
associated with intelligence.
Further particularities of the study setting make the study
valuable and novel within cognitive epidemiology. Partici-
pants within the trial are deciding whether or not to continue
a medication for a theoretical beneﬁt. Their blood pressure
readings suggest a possible future problem, but not one that is
as yet symptomatic, and the risks are communicated to them.
They are not certain to be taking the active medication; they
have a 50% chance of being on placebo. In this regard, taking
part in the trial might be driven by altruism to some extent,
because persisting with the medication could add to the
greater good by adding to medical knowledge, and verbal
intelligence might be related to that aspect. They are aware
that it is not known whether even the active medication is
effective in reducing risk of cardiovascular disease in people at
risk as deﬁned by their ABI, which is why the study was being
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active medication and it was effective overall in trials, it
would be helpful to them individually. The medication could
have side effects. In the face of all this uncertainty, they were
expected to take the medication daily.
In summary, this study explores whether intelligence is
among the factors that inﬂuence long-term compliance in a
situation where the risk of illness and the likelihood of
treatment being present and effective are uncertain. This is
likely to be representative of many pro-health decisions,
which must be taken in the face of uncertain evidence and
then persisted with. Because of the information gathering and
decisionmaking required, and the subsequent requirement to
aim at a distant goal, we hypothesise that intelligence
differences will be important.
2. Methods
2.1. Participants
The Aspirin for Asymptomatic Atherosclerosis (AAA) trial
is an on-going double-blind, placebo-controlled, randomised
clinical trial that has been conducted in central Scotland
(Lanarkshire, Edinburgh and Glasgow), United Kingdom,
since 1998 (Price et al., 2008). The International Standard
Randomised Controlled Trial Number is ISRCTN66587262.
Written informed consent was obtained from all participants
prior to the start of the trial. Volunteers aged 50 to 76 years
(some were 77 by the time they were tested) were recruited
by direct mailing of people registered with participating
general practices in the study area. 83% of practices contacted
agreed to participate. People were not eligible to attend for
screening of their ABI and subsequent randomisation into the
trial if they had a previous history of myocardial infarction or
stroke, or if they were already taking aspirin or warfarin for
any reason. In the study's recruitment information sheet, and
at the clinics, subjects were told that, if they had a low ABI,
then they were, “one of the people more likely to suffer from
heart disease or strokes in the future”.
2.2. Assessment of ankle brachial index
Potential participants attended a screening clinic at which
their ABI was calculated as the ratio of the lowest systolic
blood pressure in either ankle (dorsalis pedis or posterior
tibial) to the higher of the left or right arm systolic pressures.
Exclusion criteria included: an ABI N0.95 in both legs; taking
aspirin, other antiplatelet or anticoagulant treatment; severe
indigestion; clinical cardiovascular disease; chronic liver or
kidney disease; undergoing chemotherapy; contraindications
to treatment with aspirin; or an abnormally high or low
plasma haematocrit on a blood sample taken at the clinic.
Eligible participants were assessed for smoking status:
current, previous, or never. The deprivation of their area of
current residence was assessed using the Carstairs andMorris
index (Carstairs & Morris, 1991).
2.3. Assessment of verbal intelligence
A baseline measure of cognitive function was made at
around 3 months after participants had been randomised to,and started the trial medication (aspirin or placebo).
Cognitive function was a secondary outcome of the trial.
Participants were asked to complete a version of the Mill Hill
Vocabulary Scale, which assesses verbal intelligence (Raven,
Raven, & Court, 1998). The version used was the combined 44
synonyms of the Junior and Senior Form A tests. For each item
the participants chose which of six answer options was
closest in meaning to the target word. The total number of
items correct out of a possible 44 was used to indicate verbal
intelligence. Verbal intelligence, especially as assessed by
vocabulary tests, peaks in mid-life and deteriorates little with
age and, therefore, is an indication of a person's level of peak
prior ability (Salthouse, 2004; Schaie, 2005).
2.4. Assessment of compliance with trial medication
Participants were randomised to aspirin (enteric coated
100mg daily) or placebo. Both preparations were provided by
Bayer HealthCare plc. Participants were reviewed annually
either in a research clinic or by telephone. They were also
encouraged to contact the trial ofﬁce at any time if they went
into hospital or stopped their study medication. If partici-
pants were prescribed aspirin or another antiplatelet drug
(including prescription following a cardiovascular event) or
started to self-medicate with aspirin, then their study
medication was discontinued. If a participant stopped their
study medication for any period other than for medical
reasons, they were encouraged to re-start. Participants were
provided with a diary in which to record whether or not they
took their study medication as requested. Self-reported
compliance was assessed at each subject's annual review. A
specially trained nurse asked questions to determine:
whether participants were currently taking their medication;
whether they had taken their medication for two thirds or
more of the preceding year; and, if they had stopped their
medication, on what date this had occurred. Supplies of
tablets were renewed annually by post.
If participants had stopped taking medication then a
reason for non-compliance and the date of stopping were
noted. Reasons for stopping were as follows: ‘changed their
mind’, moved away, allergic to aspirin, other aspirin-related
symptoms (nosebleed, dyspepsia or indigestion, bruising,
blood loss from stomach or gut, ulcer, anaemia), other
symptoms, started on aspirin by their General Practitioner,
started self-medication with aspirin, started medication
contraindicated with aspirin, or death. We did not expect
differences between those who persisted with medication
and thosewho stopped for medical reasons. The hypothesis of
the present study was based upon the comparison between
those who were still complying versus those still alive but
who had stopped their study medication because they had
‘changed their mind’; that is, those for whom no medical
reason for discontinuing medication could be discerned.
2.5. Statistical analyses
Cox proportional hazards regression was used to quantify
the associations between the predictor variables and the
outcome, which was whether or not participants were still
taking medication at 2 years after entering the study. Verbal
intelligence, sex, smoking status, and deprivation index were
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stopping medication (HR 1.00, 95% CI 0.97 to 1.02, p=0.78)
and had no effect on other estimates of risk when it was
included in the models. It was omitted from the models
reported here. Time to stopping medication was measured
from the day participants took the Mill Hill Vocabulary test.
When analyses were repeated using time measured from the
point of randomisation the hazard ratio and 95% CI for
stopping medication according to Mill Hill Vocabulary Scale
score were identical.
3. Results
Fig.1 shows how the present study's analytical samplewas
derived from the 3350 participants who were randomised in
the AAA trial. In total, 2368 participants were taking the study
medication and agreed to take the Mill Hill Vocabulary Scale,
which was administered a mean of 103 (SD=26.2) days after
randomisation. Two years after starting medication there was
an analytic sample of 1993 individuals: 1828 were still taking
medication and 165 had stopped because they had ‘changed
their mind’. In addition, 363 participants had stopped taking
the medication for medical reasons, 4 because they had
moved away from the area, and 8 subjects had died (seeFig. 1. Consort ﬂow chart showing how the analytical sample was derived
from the participants whowere randomised in the AAA trial. ⁎Aspirin-related
symptoms, N=125; other symptoms, N=113; started prescribed aspirin,
N=107; self-medicated with aspirin, N=11; started contraindicated
medication, N=7. †Moved away, N=4; died, N=8.Fig. 1). There was no signiﬁcant difference in mean Mill Hill
Vocabulary Scale score between those who continued to take
medication for two years (31.5, SD 4.6), those who given up
medication for medical reasons (31.4, SD 4.5), and those who
were not taking medication because they had moved away or
died (32.0, SD, 3.8). Participants who had given up medica-
tion because they had ‘changed their mind’ had a mean Mill
Hill Vocabulary score that was signiﬁcantly lower than those
of participants in these other groups (30.1, SD 4.0; pb0.001,
Cohen's d=0.32). The analysis that follows is based on the
1993 participants in the two groups who either continued to
take medication for two years or who stopped it because they
had ‘changed their mind’.
Based on one standard deviation advantage in Mill Hill
Vocabulary Scale scores, the hazard ratio (HR) (95% CI, p) for
stopping medication by two years into the study was 0.75
(0.64 to 0.87, pb0.001). When sex was included in the model
the HR for Mill Hill Vocabulary was unchanged, and the effect
of sex was non-signiﬁcant: 1.00 (0.71 to 1.41, p=0.99). In a
model which included smoking status, the HR for Mill Hill
Vocabulary Scale score was unchanged. In this model
smoking was also a signiﬁcant predictor of stopping medica-
tion. Compared with the never-smoked group, the HRs for
current smokers and ex-smokers were 1.97 (1.34 to 2.91,
pb0.001), and 1.52 (1.02 to 2.25, p=0.04), respectively. In a
model which included the deprivation category of the
person's current residence, the HR for Mill Hill Vocabulary
Scale score was almost unattenuated (0.74, 0.63 to 0.87,
pb0.001). In this model deprivation category was not a
signiﬁcant predictor of stopping medication. None of the six
more afﬂuent categories differing signiﬁcantly from the most
deprived (category 7) as regards risk of stopping medication
(p=0.65).
Fig. 2 shows the survival curves of continuing medication
by quartile of Mill Hill Vocabulary Scale score. There were
marked differences in the proportion continuing medication
between people in the highest quarter of the distribution and
those in the remaining three quarters. People in the top and
bottom quarters of the distribution had the lowest and
highest risks, respectively, of stopping medication during the
two-year follow-up. The two middle quartiles of IQ scores fell
between these, but not in the order that would indicate a
straightforward dose–response effect across the four quar-
tiles. There was a signiﬁcant trend across the quartiles
(p=0.005). By comparison with the highest (fourth) IQ
quartile, the relative rates (HR [95% CI, p]) of the other three
quartiles were: lowest=2.53 (1.52 to 4.22, pb0.001);
second=1.93 (1.14 to 3.27, p=0.015); third=2.11 (1.15 to
3.58, p=0.005).
4. Discussion
In a randomised, placebo-controlled trial of aspirin for
asymptomatic atherosclerosis, people with higher verbal
intelligence were less likely to change their mind about
continuing to take medication during an observational period
of two years. People in the highest quartile of verbal
intelligence were especially likely to continue with their
medication; by comparison, the people in the lowest IQ
quartile had 2.5 times the risk of stopping medication. Sex,
smoking and level of deprivation did not attenuate the effects.
Fig. 2. Survival curves for stopping medication according to quarters of the distribution of Mill Hill Vocabulary Scale score.
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signiﬁcantly increased risk of stopping medication, indepen-
dently of verbal intelligence. Therefore, whatever else it is
related to in health decision-making, intelligence differences
are associated with persevering in the medium-to-long term
with a course of health actions to which one has already
subscribed.
Strengths of the study include the large number of
subjects, the double-blind, randomised and placebo-con-
trolled design, and the long follow-up period. It is a feature,
and possibly a limitation, of the study that the Mill Hill
Vocabulary Scale was not administered until about three
months after the randomisation to medication or placebo
took place. However, we think this could be a strength, insofar
as the decision to take the test was the last in a long line of
health-relevant decisions made in the afﬁrmative. The study
shows that, even after all of these pro-health decisions,
people who just change their minds thereafter have lower
average intelligence.
The present study is valuable because it models much of
what is important in avoiding the now-common chronic
conditions that especially affect older people. There are some
health settings where there is an unequivocal and proximal
correct course—such as maintaining good glycaemic balance
in diabetes in children—and there is evidence that parental
intelligence is related to that (Ross, Frier, Kelnar, & Deary,
2001). The present study models a different, more protean
part of real life. Health-related decisions have to be made and
stood by in the face of uncertainty about whether they are
correct, or of beneﬁt to the individual making them. It might
be that what characterises intelligence in health self-care is
the willingness to persist in playing the odds for a best-guess
theoretical beneﬁt, and the taking of a long view as regards
behaviour. This style of behaviour might be a consequence of
a mental capacity that can understand that there are multiple
small risks to health, and appreciate the need to plan one's life
to overcomemany of them. This type of behaviour is, perhaps,more easily evinced in a social setting that is correlated with
higher intelligence. However, if such social mediationwas the
explanation for our ﬁndings then we would expect the
strength of the association between intelligence and com-
pliance with medication to be more strongly attenuated by
level of deprivation.
The present study can be used as a foundation for future
studies. These might add education and measures of health
literacy as possible mediators of the inﬂuence of intelligence
on adherence to treatments in the longer term. However, care
would have to be taken with regard to which measures of
health literacy are used. These vary considerably in content,
which can involve the pronunciation of words, the under-
standing of written material, or the computation of solutions
from numerical data.
It is also important to develop the present study's ﬁndings
and provide more insight into other person-level variables,
including social cognition, that might explain people's health-
related decision making. Of particular relevance would be an
examination of the role of illness cognitions. Thus, future
research could include consideration of the ﬁndings that
patients' beliefs about medicines are associated with adher-
ence to treatment (Horne & Weinman, 1999). The beliefs that
correlate with adherence to treatment include the necessity
of taking medicines for the given condition, and the person's
concerns about factors such as side effects and dependence. In
Horne & Weinman's study these medication beliefs were a
stronger predictor of adherence than sociodemographic
factors. Intelligence might be a contributing factor to these
assessments, and help to explain how patients' analysis of
cost/beneﬁt is important in determining compliance with
treatment. In the present study we were not able to explore
how patients in the trial perceived their risk of possible illness
and how the treatment might affect it. It would also be useful
in future to investigate how effective patients perceived
aspirin to be, and their views of the importance for future
health of taking it consistently. Future research might also
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health-related decision making. For example, women who
reported omitting taking medication for breast cancer had
lower internal locus of control (Atkins & Fallowﬁeld, 2006).
The possible role of locus of control is boosted by the ﬁnding
that a higher locus of control in childhood contributes to
better health outcomes and behaviours at age 30 (Gale, Batty,
& Deary, 2008). Moreover, in this latter study the contribution
of locus of control was additional to that contributed by
higher childhood IQ, and might partly have mediated the
effect of childhood IQ.
In conclusion, the present study ﬁnds a novel and
important aspect of health self-management that is asso-
ciated with verbal intelligence. Further research should
investigate the mechanisms of the association, which will
point to ways of promoting optimal health behaviours,
irrespective of intelligence level. In addition, the ﬁndings
might provide a part of the as-yet elusive explanations for the
association between intelligence and survival (Whalley &
Deary, 2001).
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